Milestone Pharmaceuticals’ (MIST) Buy Rating Reiterated at HC Wainwright

Milestone Pharmaceuticals (NASDAQ:MIST)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They currently have a $25.00 price target on the stock.

Milestone Pharmaceuticals Stock Performance

NASDAQ:MIST opened at $1.75 on Friday. The company has a debt-to-equity ratio of 2.18, a quick ratio of 15.40 and a current ratio of 15.40. Milestone Pharmaceuticals has a fifty-two week low of $1.12 and a fifty-two week high of $2.75. The company has a 50 day simple moving average of $2.06 and a two-hundred day simple moving average of $1.76. The company has a market capitalization of $93.06 million, a PE ratio of -2.17 and a beta of 1.80.

Institutional Trading of Milestone Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of MIST. Jones Financial Companies Lllp lifted its position in Milestone Pharmaceuticals by 1,000.0% in the 4th quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company’s stock valued at $26,000 after acquiring an additional 10,000 shares in the last quarter. National Bank of Canada FI boosted its position in shares of Milestone Pharmaceuticals by 163.4% during the fourth quarter. National Bank of Canada FI now owns 18,700 shares of the company’s stock valued at $44,000 after buying an additional 11,600 shares during the last quarter. PVG Asset Management Corp bought a new stake in Milestone Pharmaceuticals during the third quarter worth $46,000. Atria Investments Inc grew its holdings in Milestone Pharmaceuticals by 44.4% during the third quarter. Atria Investments Inc now owns 40,421 shares of the company’s stock worth $61,000 after buying an additional 12,430 shares in the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new stake in Milestone Pharmaceuticals in the 4th quarter valued at $73,000. Institutional investors own 86.18% of the company’s stock.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.